author-photo

Lyudmila Bazhenova

University of California, San Diego

242

Papers

6939

Citations

Citation Trend

Filter By

Papers (167) Sort By

Journal Conference Others

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (35)
Abstract 394: Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.

2021 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
P01.23 Veliparib (V) in Combination with Carboplatin/Paclitaxel (C/P)-Based Chemoradiotherapy (CRT) in Patients With Stage III NSCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer.

2021 Expert Opinion on Pharmacotherapy
Show All
- Source
- Cite
- Save
Citations (0)